Posts tagged TSX
Crescita targeting $50-million in revenue in 5 years

Crescita Therapeutics (TSX:CTX), is aiming to be a $50-million commercial dermatology company in the next five years, with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, their diseases and their symptoms.

Read More
Zymeworks platforms validated by pharma partnerships

Zymeworks’ (NYSE, TSX:ZYME) marquee partnerships with Merck, Eli Lilly, Celgene, GlaxoSmithKline and Daiichi-Sankyo provide validation for its next-generation oncology platforms, with the potential for $4.1-billion in milestone payments.

Read More
Tetra Bio-Pharma sets active cannabis clinical programs

Tetra Bio-Pharma (OTCQB:TBPMF; CSE:TBP) has an aggressive clinical trial program set to begin in the final quarter this year and first quarter of 2018 to prove the efficacy and safety of at least three therapeutic cannabis products.

Read More
FeatureLeonard ZehrTetra, Tetra Bio-Pharma, OTCQB, OTCQB:TBPMF, TBPMF, CSE, CSE:TBP, TBP, clinical trial, therapeutic cannabis products, cannabis, cannabis products, natural health cannabis, natural health, Andre Rancourt, topical treatment, pain management, cardiovascular disease, athletic performance, skin care, topical cream, sales and marketing, branding, distribution, Phyto Pain Pharma, cannabis-based drug products, Agro Tek, Grow Pros, marijuana, recreational marijuana company, global leader, nutraceuticals, toxic, toxic side effects, steroids, Health Canada, FDA, insurance companies, PPP001, smokeable marijuana, advanced cancer pain, cancer pain, cancer, pellet, titanium inhalation device, digital readout, consumption, Aphria, OTCQB:APHQF, APHQF, TSX, TSX:APH, APH, licensed producer, active pharmaceutical ingredient, Phase 1 study, safety data, pharmacokinetic data, tetrahydrocannabinol, THC, pain relief, cancer patients, Phase 1 trial, Phase 3 clinical trial, chemical entity, pivotal trial, Notice of Compliance, ACMPR, opioids, severe pain, IntelGenx, OTCQX, OTCQX:IGXT, IGXT, TSXV, TSXV:IGX, IGX, oral mucoadhesive, dronabinol XL tablet, cheek, AdVersa controlled-release technology, THC tablet, synthetic THC, North American patients, anorexia, cancer chemotherapy-related pain, chemotherapy-related pain, PPP002, Phase 2 trial, Division of Anesthesia, Analgesia, Addiction Products, and Addiction Products, 505(b)(2) regulatory filing, 505(b)(2), regulatory filing, Dronabinol XL AdVersa Mucoadhesive tablet, dry eye disorder, ocular pain, inflammation, Panag Pharma, proof-of-concept, cannabinoid eye drop, eye drop, PPP003, exema, general neuropathic pain, business model, pharmaceutical relevance
Canopy Health aims to evolve medical cannabis as a natural drug product and disrupt pharma market

As president and CEO of newly formed Canopy Health Innovations, a spin off of Canopy Group (TSX:WEED), a world leading diversified cannabis company, Marc Wayne is a pioneer of the medical cannabis sector. He was a co-founder of Bedrocan Canada, one of Canada’s first licensed producers of medical cannabis, and founding chairman of the Cannabis Canada Association, a trade group with 17 licensed producers...

Read More
Microbix in talks with investors for Kinlytic relaunch

Following a meeting with the FDA last month, Microbix Biosystems (TSX:MBX) is entertaining expressions of interest from potential partners to license or acquire its anti-clotting urokinase drug, which has been rebranded as Kinlytic, and also provide funding for its re-launch in the U.S. market.

Read More
GeneNews aims to fix compliance gap in early cancer screening

GeneNews (TSX:GEN) is addressing the major issue in earlycancer screening - patient reluctance with inconvenient and intrusive screening methods - with a suite of differentiated molecular diagnostic tests that rely on a convenient in-office blood draw to find cancers of the colon, lung, breast and prostate, early.

Read More
3D Signatures seeking partners for genomic imaging platform

3D Signatures (TSX-V:DXD) which has developed proprietary software with the potential to analyze a patient’s chromosomal arrangement, or signature, is seeking collaborations to advance its TeloView platform in the areas of Hodgkin’s lymphoma, prostrate cancer, multiple myeloma and Alzheimer’s disease.

Read More
Immunovaccine targets three clinical milestones

Immunovaccine (OTCQX:IMMVF; TSX:IMV) expects to report three clinical milestones for its killer T cell activation vaccine platform, DepoVax, in ovarian and HPV cancers in the next 12 months.

Read More
Lupus Foundation puzzled by negative reaction to Aurinia data

As president and CEO of The Lupus Foundation of America (LFA), a role she has held for 15 years, Sandra Raymond is an outspoken advocate for the plight of lupus patients. She has worked with the board of directors and the lupus research community to bring national attention and resources to lupus research and education. Ms. Raymond came to the LFA after serving as the founding CEO of the National Osteoporosis Foundation, beginning in 1986. She envisions great progress in lupus treatment and care over the next 10 years but recognizes the urgent need to elevate lupus on the national healthcare agenda by increasing federal and private investment in research on lupus and developing constructive public policies aimed at bringing support and services to all people affected by lupus. In this interview with BioTuesdays.com, Ms. Raymond discusses the state of the disease and results of a recent clinical study by Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP).

Read More
FeatureLeonard ZehrThe Lupus Foundation of America, LFA, Sandra Raymond, lupus research community, National Osteoporosis Foundation, lupus treatment, national health care, Aurinia Pharmaceuticals, Aurinia, NASDAQ:AUPH, NASDAQ, AUPH, TSX:AUP, TSX, AUP, autoimmune disease, immune system, healthy tissues, inflammation, organ damage, life-threatening, treatments, joint damage, skin rashes, extreme fatigue, hair loss, kidneys, lungs, cardiovascular, brain, disease flares, treatment regimens, mortality, genetics, hormonal factors, environmental triggers, imbalance, bacteria, organ, tissue, sun exposure, lupus, lupus flares, butterfly-shaped rash, cheeks, bridge of the nose, organ systems, mortality statistics, renal disease, cardiovascular disease, infections, memorial donations, pioneering physicians, steroids, chemotherapies, Benlysta, mouth sores, hyperactive immune system, osteoporosis, bone fractures, insomnia, diabetes, infertility, blood system, nervous system, disorders, breast cancer, breast cancer patients, lupus kidney disease, chemo, tissue damage, kidney disease, lupus nephritis, Phase 2 trial, Phase 3 trial, Aurinia’s voclosporin, scientific literature, Bristol Myers-Squibb’s trial, Abatacept, mycophenolate mofetil, Asia, research initiatives, national and international awareness campaigns, fostered national legislation, education programs, biology, new medications, private sector, FDA, clinical trials, disease activity instrument, questionnaire, global biopharmaceutical company, global movement
BioSyent to target international markets

BioSyent (OTC:BIOYF; TSX-V:RX) is actively building its international pharmaceutical sales and marketing business, adding products licensed and sold internationally to products already being shipped from Canada.

“We’re working on a couple of international deals now,” René Goehrum, chairman, president and CEO, says in an interview with BioTuesdays.com.

Mr. Goehrum explains that BioSyent hopes to commercialize new product deals in the Middle East, Latin America and Southeast Asia. “These products may not be licensed for sale in Canada.”

Read More
Merus Labs moving up the value chain

After an 18-month company transformation under new CEO, Barry Fishman, Merus Labs International (NASDAQ:MSLI; TSX:MSL) is now ready to in-license new pharmaceutical products, in addition to optimizing existing products and continuing to acquire legacy products that are no longer strategic for major pharmaceutical companies.

“Since the fall of 2014, we’ve strengthened the management team and European platform, acquired additional products and improved the balance sheet and cash flow,” Mr. Fishman says in an interview with BioTuesdays.com.

Read More
Microbix validating new virology production process

Microbix Biosystems (TSX:MBX) is validating a new bioreactor manufacturing platform for its world-leading line of viral and bacterial antigens and other virology products ahead of a full roll-out to customers towards the end of 2016.

“Once the new platform is fully implemented, it will reduce our manufacturing costs, greatly expand our available capacity and improve our carbon footprint,” president and CEO, Vaughn Embro-Pantalony, says in an interview with BioTuesdays.com.

Antigens are the key reactive components used in diagnostic tests and vaccine research. Microbix was founded in 1988 around the virology business, culturing and purifying antigens for use in research, diagnostic testing, and vaccine development.

Read More
In conversation with Charles Haff

As a senior research analyst at Craig-Hallum Capital Group, Charles Haff covers medical devices and ancillary healthcare services. Previously, he covered medical devices at Dougherty & Company and was a buy side healthcare analyst for 12 years at Thrivent Asset Management, a Minneapolis insurance company, Security Global Investors and JPMorgan Asset Management, where he covered all sectors within health care. Mr. Haff tends not to think about his coverage universe in a vacuum but by tapping his broad background, he understands how companies fit into the healthcare ecosystem and researches those companies. Mr. Haff earned his B.S. from the University of Nevada, Las Vegas and his M.B.A. from Xavier University. In this interview with BioTuesdays.com, he discusses industry trends in the healthcare sector and a couple of his favorite investment ideas.

Read More
CRH Medical to consolidate GI anesthesia market

With four acquisitions and a joint venture under its belt over the past 10 months, CRH Medical (NYSE MKT:CRHM; TSX:CRH) is in talks to continue consolidating the large and fragmented market of gastrointestinal (GI) anesthesia providers that serve the GI market.

“Our goal is to be the leader in GI-focused anesthesia by leveraging the reputation we’ve established and relationships we’ve built through our CRH O’Regan System for gastroenterologists performing hemorrhoid ligation,” CEO, Edward Wright, says in an interview with BioTuesdays.com.

The company created a paradigm shift in the GI sector with the CRH O’Regan System by giving gastroenterologists an opportunity to effectively treat hemorrhoids, which they often diagnose during colonoscopy procedures for colon cancer screening. That opened an untapped revenue stream for gastroenterologists.

Read More
In conversation with Arun Menawat

As president and CEO of Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ), Arun Menawat has led the company through a strategic transformation this year into a direct sales company from one originally dependent on partners to distribute its SPY fluorescent imaging solutions for the operating room. Novadaq’s pioneering imaging platform helps surgeons intraoperatively visualize critical structures including blood vessels, microvasculature and clinically relevant physiology that results in better patient outcomes and reduced healthcare costs. The company now sells three products with its own sales team: SPY Elite for open surgery and PINPOINT for minimally invasive surgery, as well as LUNA for wound care in hospitals and outpatient clinics. Novadaq retains an alliance with Intuitive Surgical (NASDAQ:ISRG) to integrate and supply Firefly SPY imaging into Intuitive’s da Vinci surgical robotic system. In this interview with BioTuesdays, Dr. Menawat discusses the evolution of Novadaq’s business model, new product innovations and co-marketing agreements, and its product pipeline.

Read More
Neovasc launching Reducer in Europe for RA

Neovasc (NASDAQ:NVCN; TSX:NVC) has begun an initial launch in Europe to introduce its implantable Reducer medical device for the treatment of refractory angina (RA) in advanced-stage cardiovascular patients.

 

Alexei Marko

“Our aim is have distributors selling Reducer in Switzerland, Italy and the UK, while in Germany, we’ll use a combination of distributors and our own sales reps,” CEO, Alexei Marko, says in an interview with BioTuesdays.com.

“If the results of the initial rollout are favorable, we’ll explore a full commercial launch in the EU,” he adds.

Read More